表紙:がんバイオマーカーの世界市場:プロファイリング技術別、生体分子別、がんの種類別、用途別の機会分析と業界予測:2020年~2027年
市場調査レポート
商品コード
944148

がんバイオマーカーの世界市場:プロファイリング技術別、生体分子別、がんの種類別、用途別の機会分析と業界予測:2020年~2027年

Cancer Biomarkers Market by Profiling Technology, Biomolecule, Cancer Type, and Application : Global Opportunity Analysis and Industry Forecast, 2020-2027

出版日: | 発行: Allied Market Research | ページ情報: 英文 338 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=114.77円
がんバイオマーカーの世界市場:プロファイリング技術別、生体分子別、がんの種類別、用途別の機会分析と業界予測:2020年~2027年
出版日: 2020年04月01日
発行: Allied Market Research
ページ情報: 英文 338 Pages
納期: 2-3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のがんバイオマーカー市場は、2019年の109億4,408万米ドルから2027年には269億7,950万米ドルに拡大すると予測されており、2020年から2027年までのCAGRは11.8%になる見通しです。がんバイオマーカーは、体内のがん細胞の存在を示す追跡可能な物質または分子であり、さまざまな診断技術を使用して各種のがんバイオマーカーを診断し、分析することにより、がんを早期段階で治療することができます。がんバイオマーカーには、タンパク質、ペプチド、抗体、核酸などさまざまな種類があり、組織、尿、血清、血液などの体液中にこれらが存在するということは、がんに罹患している可能性を示唆しています。市場拡大の原動力となるのは、乳がん、前立腺がん、肺がんなどさまざまな種類のがんの有病率増加、生物学的および標的薬物療法の重要性の高まり、技術の進歩、がんバイオマーカーの正確性と信頼性の向上、がん診断法の研究開発に向けた官民の投資拡大などの要因です。

当レポートは、世界のがんバイオマーカー市場を調査したもので、市場の概要、プロファイリング技術別、生体分子別、がんの種類別、用途別、地域別の分析、競合情勢、主要企業のプロファイルなどの情報を提供しています。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場の概要

  • 市場の定義と範囲
  • バイオマーカー診断と従来の診断
  • 主な調査結果
  • ポーターのファイブフォース分析
  • 主要企業の立ち位置
  • 市場の力学
    • 成長促進要因
    • 成長阻害要因
    • 市場機会
    • 影響分析
  • 特許分析
  • 臨床試験分析

第4章 市場分析:プロファイリング技術別

  • 概要
    • 市場規模と予測
  • オミクス技術
    • 市場の主なトレンドと成長機会
    • 市場規模と予測:地域別
    • 市場分析:国別
    • 市場規模と予測:タイプ別
    • ゲノミクス
    • プロテオミクス
    • その他
  • 画像診断技術
    • 市場の主なトレンドと成長機会
    • 市場規模と予測:地域別
    • 市場分析:国別
    • 市場規模と予測:タイプ別
    • 磁気共鳴画像法(MRI)
    • 陽電子放出断層撮影(PET)
    • コンピュータ断層撮影(CT)
    • マンモグラフィー
    • 超音波
  • 免疫学的検定
    • 市場の主なトレンドと成長機会
    • 市場規模と予測:地域別
    • 市場分析:国別
    • 市場規模と予測:タイプ別
    • 免疫組織化学(IHC)検査
    • 酵素免疫測定吸着法(ELISA)
    • フローサイトメトリー
  • 細胞遺伝学ベースのテスト
    • 市場の主なトレンドと成長機会
    • 市場規模と予測:地域別
    • 市場分析:国別
    • 市場規模と予測:タイプ別
    • In-situハイブリダイゼーション
    • その他

第5章 市場分析:生体分子別

  • 概要
    • 市場規模と予測
  • 遺伝的バイオマーカー
    • 市場規模と予測:地域別
    • 市場分析:国別
  • タンパク質バイオマーカー
    • 市場規模と予測:地域別
    • 市場分析:国別
  • 糖鎖バイオマーカー
    • 市場規模と予測:地域別
    • 市場分析:国別
第6章 市場分析:がんの種類別
  • 概要
    • 市場規模と予測
  • 乳がん
    • 市場規模と予測:地域別
    • 市場分析:国別
  • 肺がん
    • 市場規模と予測:地域別
    • 市場分析:国別
  • 大腸がん
    • 市場規模と予測:地域別
    • 市場分析:国別
  • 前立腺がん
    • 市場規模と予測:地域別
    • 市場分析:国別
  • 胃がん
    • 市場規模と予測:地域別
    • 市場分析:国別
  • その他
    • 市場規模と予測:地域別
    • 市場分析:国別

第7章 市場分析:用途別

  • 概要
    • 市場規模と予測
  • 診断
    • 市場規模と予測:地域別
    • 市場分析:国別
  • 創薬と開発
    • 市場規模と予測:地域別
    • 市場分析:国別
  • 予後
    • 市場規模と予測:地域別
    • 市場分析:国別
  • リスク評価
    • 市場規模と予測:地域別
    • 市場分析:国別
  • その他
    • 市場規模と予測:地域別
    • 市場分析:国別

第8章 市場分析:地域別

  • 概要
    • 市場規模と予測
  • 北米
    • 市場の主なトレンドと機会
    • 市場分析:国別
    • 市場規模と予測:プロファイリング技術別
    • 市場規模と予測:生体分子別
    • 市場規模と予測:がんの種類別
    • 市場規模と予測:用途別
  • 欧州
    • 市場の主なトレンドと機会
    • 市場分析:国別
    • 市場規模と予測:プロファイリング技術別
    • 市場規模と予測:生体分子別
    • 市場規模と予測:がんの種類別
    • 市場規模と予測:用途別
  • アジア太平洋
    • 市場の主なトレンドと機会
    • 市場分析:国別
    • 市場規模と予測:プロファイリング技術別
    • 市場規模と予測:生体分子別
    • 市場規模と予測:がんの種類別
    • 市場規模と予測:用途別
  • ラテンアメリカ・中東・アフリカ
    • 市場の主なトレンドと機会
    • 市場分析:国別
    • 市場規模と予測:プロファイリング技術別
    • 市場規模と予測:生体分子別
    • 市場規模と予測:がんの種類別
    • 市場規模と予測:用途別

第9章 企業プロファイル

  • Abbott Laboratories
  • BIO-RAD LABORATORIES, INC.
  • Bristol-Myers Squibb Company
  • EXACT SCIENCES CORPORATION
  • F. HOFFMANN-LA ROCHE LTD.
  • Merck KGaA
  • PERKINELMER、INC.
  • QIAGEN NV
  • Siemens AG
  • THERMO FISHER SCIENTIFIC、INC.
図表

LIST OF TABLES

  • TABLE 01.CONVENTIONAL DIAGNOSTICS VS. DIAGNOSTIC BIOMARKER TECHNIQUES
  • TABLE 02.GLOBAL CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGIES, 2019-2027 ($MILLION)
  • TABLE 03.OMIC TECHNOLOGIES CANCER BIOMARKERS MARKET, BY REGION, 2019-2027 ($MILLION)
  • TABLE 04.OMIC TECHNOLOGIES CANCER BIOMARKERS MARKET, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 05.GENOMICS CANCER BIOMARKERS MARKET, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 06.PROTEOMICS CANCER BIOMARKERS MARKET, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 07.OTHER OMIC TECHNOLOGIES CANCER BIOMARKERS MARKET, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 08.IMAGING TECHNOLOGIES CANCER BIOMARKERS MARKET, BY REGION, 2019-2027 ($MILLION)
  • TABLE 09.IMAGING TECHNOLOGIES CANCER BIOMARKERS MARKET, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 10.IMMUNOASSAYS CANCER BIOMARKERS MARKET, BY REGION, 2019-2027 ($MILLION)
  • TABLE 11.IMMUNOASSAYS CANCER BIOMARKERS MARKET, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 12.CYTOGENETICS-BASED TESTS CANCER BIOMARKERS MARKET, BY REGION, 2019-2027 ($MILLION)
  • TABLE 13.CYTOGENETICS-BASED TESTS CANCER BIOMARKERS MARKET, BY REGION, 2019-2027 ($MILLION)
  • TABLE 14.GLOBAL CANCER BIOMARKERS MARKET, BY BIOMOLECULE, BY BIOMOLECULE, 2019-2027 ($MILLION)
  • TABLE 15.GENETIC BIOMARKERS CANCER BIOMARKERS MARKET, BY REGION, 2019-2027 ($MILLION)
  • TABLE 16.PROTEIN BIOMARKERS CANCER BIOMARKERS MARKET, BY REGION, 2019-2027 ($MILLION)
  • TABLE 17.GLYCO-BIOMARKERS CANCER BIOMARKERS MARKET, BY REGION, 2019-2027 ($MILLION)
  • TABLE 18.GLOBAL CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2019-2027 ($MILLION)
  • TABLE 19.BREAST CANCER BIOMARKERS MARKET, BY REGION, 2019-2027 ($MILLION)
  • TABLE 20.LUNG CANCER BIOMARKERS MARKET, BY REGION, 2019-2027 ($MILLION)
  • TABLE 21.COLORECTAL CANCER BIOMARKERS MARKET, BY REGION, 2019-2027 ($MILLION)
  • TABLE 22.PROSTATE CANCER BIOMARKERS MARKET, BY REGION, 2019-2027 ($MILLION)
  • TABLE 23.STOMACH CANCER BIOMARKERS MARKET, BY REGION, 2019-2027 ($MILLION)
  • TABLE 24.OTHERS CANCER BIOMARKERS MARKET, BY REGION, 2019-2027 ($MILLION)
  • TABLE 25.GLOBAL CANCER BIOMARKERS MARKET, BY APPLICATION, 2019-2027 ($MILLION)
  • TABLE 26.DIAGNOSTICS CANCER BIOMARKERS MARKET, BY REGION, 2019-2027 ($MILLION)
  • TABLE 27.DRUG DISCOVERY AND DEVELOPMENT CANCER BIOMARKERS MARKET, BY REGION, 2019-2027 ($MILLION)
  • TABLE 28.PROGNOSTICS CANCER BIOMARKERS MARKET, BY REGION, 2019-2027 ($MILLION)
  • TABLE 29.RISK ASSESSMENT CANCER BIOMARKERS MARKET, BY REGION, 2019-2027 ($MILLION)
  • TABLE 30.OTHERS CANCER BIOMARKERS MARKET, BY REGION, 2019-2027 ($MILLION)
  • TABLE 31.CANCER BIOMARKERS MARKET, BY REGION, 2018-2026 ($MILLION)
  • TABLE 32.NORTH AMERICA CANCER BIOMARKERS MARKET REVENUE, BY COUNTRY 2019-2026 ($MILLION)
  • TABLE 33.THE U.S. CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019-2027 ($MILLION)
  • TABLE 34.THE U.S. CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019-2027 ($MILLION)
  • TABLE 35.THE U.S. CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019-2027 ($MILLION)
  • TABLE 36.THE U.S. CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019-2027 ($MILLION)
  • TABLE 37.CANADA CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019-2027 ($MILLION)
  • TABLE 38.CANADA CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019-2027 ($MILLION)
  • TABLE 39.CANADA CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019-2027 ($MILLION)
  • TABLE 40.CANADA CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019-2027 ($MILLION)
  • TABLE 41.MEXICO CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019-2027 ($MILLION)
  • TABLE 42.MEXICO CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019-2027 ($MILLION)
  • TABLE 43.MEXICO CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019-2027 ($MILLION)
  • TABLE 44.MEXICO CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019-2027 ($MILLION)
  • TABLE 45.NORTH AMERICA CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019-2027 ($MILLION)
  • TABLE 46.NORTH AMERICA CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019-2027 ($MILLION)
  • TABLE 47.NORTH AMERICA CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019-2027 ($MILLION)
  • TABLE 48.NORTH AMERICA CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019-2027 ($MILLION)
  • TABLE 49.EUROPE CANCER BIOMARKERS MARKET REVENUE, BY COUNTRY 2019-2026 ($MILLION)
  • TABLE 50.GERMANY CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019-2027 ($MILLION)
  • TABLE 51.GERMANY CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019-2027 ($MILLION)
  • TABLE 52.GERMANY CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019-2027 ($MILLION)
  • TABLE 53.GERMANY CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019-2027 ($MILLION)
  • TABLE 54.GERMANY CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019-2027 ($MILLION)
  • TABLE 55.FRANCE CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019-2027 ($MILLION)
  • TABLE 56.FRANCE CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019-2027 ($MILLION)
  • TABLE 57.FRANCE CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019-2027 ($MILLION)
  • TABLE 58.UK CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019-2027 ($MILLION)
  • TABLE 59.UK CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019-2027 ($MILLION)
  • TABLE 60.UK CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019-2027 ($MILLION)
  • TABLE 61.UK CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019-2027 ($MILLION)
  • TABLE 62.ITALY CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019-2027 ($MILLION)
  • TABLE 63.ITALY CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019-2027 ($MILLION)
  • TABLE 64.ITALY CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019-2027 ($MILLION)
  • TABLE 65.ITALY CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019-2027 ($MILLION)
  • TABLE 66.RUSSIA CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019-2027 ($MILLION)
  • TABLE 67.RUSSIA CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019-2027 ($MILLION)
  • TABLE 68.RUSSIA CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019-2027 ($MILLION)
  • TABLE 69.RUSSIA CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019-2027 ($MILLION)
  • TABLE 70.REST OF EUROPE CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019-2027 ($MILLION)
  • TABLE 71.REST OF EUROPE CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019-2027 ($MILLION)
  • TABLE 72.REST OF EUROPE CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019-2027 ($MILLION)
  • TABLE 73.REST OF EUROPE CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019-2027 ($MILLION)
  • TABLE 74.EUROPE CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019-2027 ($MILLION)
  • TABLE 75.EUROPE CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019-2027 ($MILLION)
  • TABLE 76.EUROPE CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019-2027 ($MILLION)
  • TABLE 77.EUROPE CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019-2027 ($MILLION)
  • TABLE 78.ASIA-PACIFIC CANCER BIOMARKERS MARKET REVENUE, BY COUNTRY 2019-2026 ($MILLION)
  • TABLE 79.JAPAN CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019-2027 ($MILLION)
  • TABLE 80.JAPAN CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019-2027 ($MILLION)
  • TABLE 81.JAPAN CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019-2027 ($MILLION)
  • TABLE 82.JAPAN CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019-2027 ($MILLION)
  • TABLE 83.CHINA CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019-2027 ($MILLION)
  • TABLE 84.CHINA CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019-2027 ($MILLION)
  • TABLE 85.CHINA CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019-2027 ($MILLION)
  • TABLE 86.CHINA CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019-2027 ($MILLION)
  • TABLE 87.AUSTRALIA CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019-2027 ($MILLION)
  • TABLE 88.AUSTRALIA CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019-2027 ($MILLION)
  • TABLE 89.AUSTRALIA CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019-2027 ($MILLION)
  • TABLE 90.AUSTRALIA CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019-2027 ($MILLION)
  • TABLE 91.INDIA CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019-2027 ($MILLION)
  • TABLE 92.INDIA CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019-2027 ($MILLION)
  • TABLE 93.INDIA CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019-2027 ($MILLION)
  • TABLE 94.INDIA CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019-2027 ($MILLION)
  • TABLE 95.REST OF ASIA-PACIFIC CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019-2027 ($MILLION)
  • TABLE 96.REST OF ASIA-PACIFIC CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019-2027 ($MILLION)
  • TABLE 97.REST OF ASIA-PACIFIC CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019-2027 ($MILLION)
  • TABLE 98.REST OF ASIA-PACIFIC CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019-2027 ($MILLION)
  • TABLE 99.ASIA-PACIFIC CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019-2027 ($MILLION)
  • TABLE 100.ASIA-PACIFIC CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019-2027 ($MILLION)
  • TABLE 101.ASIA-PACIFIC CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019-2027 ($MILLION)
  • TABLE 102.ASIA-PACIFIC CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019-2027 ($MILLION)
  • TABLE 103.LAMEA CANCER BIOMARKERS MARKET REVENUE, BY COUNTRY 2019-2026 ($MILLION)
  • TABLE 104.BRAZIL CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019-2027 ($MILLION)
  • TABLE 105.BRAZIL CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019-2027 ($MILLION)
  • TABLE 106.BRAZIL CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019-2027 ($MILLION)
  • TABLE 107.BRAZIL CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019-2027 ($MILLION)
  • TABLE 108.SAUDI ARABIA CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019-2027 ($MILLION)
  • TABLE 109.SAUDI ARABIA CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019-2027 ($MILLION)
  • TABLE 110.SAUDI ARABIA CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019-2027 ($MILLION)
  • TABLE 111.SAUDI ARABIA CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019-2027 ($MILLION)
  • TABLE 112.UNITED ARAB EMIRATES CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019-2027 ($MILLION)
  • TABLE 113.UNITED ARAB EMIRATES CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019-2027 ($MILLION)
  • TABLE 114.UNITED ARAB EMIRATES CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019-2027 ($MILLION)
  • TABLE 115.UNITED ARAB EMIRATES CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019-2027 ($MILLION)
  • TABLE 116.REST OF LAMEA CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019-2027 ($MILLION)
  • TABLE 117.REST OF LAMEA CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019-2027 ($MILLION)
  • TABLE 118.REST OF LAMEA CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019-2027 ($MILLION)
  • TABLE 119.REST OF LAMEA CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019-2027 ($MILLION)
  • TABLE 120.LAMEA CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019-2027 ($MILLION)
  • TABLE 121.LAMEA CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019-2027 ($MILLION)
  • TABLE 122.LAMEA CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019-2027 ($MILLION)
  • TABLE 123.LAMEA CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019-2027 ($MILLION)
  • TABLE 124.ABBOTT: COMPANY SNAPSHOT
  • TABLE 125.ABBOTT: OPERATING SEGMENTS
  • TABLE 126.ABBOTT: PRODUCT PORTFOLIO
  • TABLE 127.BIO-RAD: COMPANY SNAPSHOT
  • TABLE 128.BIO-RAD: OPERATING SEGMENTS
  • TABLE 129.BIO-RAD: PRODUCT PORTFOLIO
  • TABLE 130.BMS: COMPANY SNAPSHOT
  • TABLE 131.BMS: PRODUCT PORTFOLIO
  • TABLE 132.EXACT SCIENCES: COMPANY SNAPSHOT
  • TABLE 133.EXACT SCIENCES: PRODUCT PORTFOLIO
  • TABLE 134.ROCHE: COMPANY SNAPSHOT
  • TABLE 135.ROCHE: OPERATING SEGMENTS
  • TABLE 136.ROCHE: PRODUCT PORTFOLIO
  • TABLE 137.MERCK GROUP: COMPANY SNAPSHOT
  • TABLE 138.MERCK GROUP: OPERATING SEGMENTS
  • TABLE 139.MERCK GROUP: PRODUCT PORTFOLIO
  • TABLE 140.PERKINELMER: COMPANY SNAPSHOT
  • TABLE 141.PERKINELMER: OPERATING SEGMENTS
  • TABLE 142.PERKINELMER: PRODUCT PORTFOLIO
  • TABLE 143.QIAGEN: COMPANY SNAPSHOT
  • TABLE 144.QIAGEN: OPERATING SEGMENTS
  • TABLE 145.QIAGEN: PRODUCT PORTFOLIO
  • TABLE 146.SIEMENS: COMPANY SNAPSHOT
  • TABLE 147.SIEMENS: OPERATING SEGMENTS
  • TABLE 148.SIEMENS: PRODUCT PORTFOLIO
  • TABLE 149.THERMO FISHER: COMPANY SNAPSHOT
  • TABLE 150.THERMO FISHER: OPERATING SEGMENTS
  • TABLE 151.THERMO FISHER: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01.GLOBAL CANCER BIOMARKERS MARKET SEGMENTATION
  • FIGURE 02.TOP INVESTMENT POCKETS
  • FIGURE 03.MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 04.MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 05.LOW THREAT OF NEW ENTRANTS
  • FIGURE 07.MODERATE COMPETITIVE RIVALRY
  • FIGURE 08.TOP PLAYER POSITIONING,
  • FIGURE 09.PIE CHART FOR CANCER CASES DIAGNOSED IN 2018
  • FIGURE 10.IMPACT ANALYSES, CANCER BIOMARKERS MARKET
  • FIGURE 11.COMPARATIVE ANALYSIS OF CANCER BIOMARKERS MARKET FOR OMIC TECHNOLOGIES, BY COUNTRY, 2019 & 2027 ($MILLION)
  • FIGURE 12.GENOMICS CANCER BIOMARKERS MARKET SIZE AND FORECAST
  • FIGURE 13.PROTEOMICS CANCER BIOMARKERS MARKET SIZE AND FORECAST
  • FIGURE 14.OTHER OMIC TECHNOLOGIES MARKET SIZE AND FORECAST
  • FIGURE 15.COMPARATIVE ANALYSIS OF CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY COUNTRY, 2019 & 2027 ($MILLION)
  • FIGURE 16.MARKET SIZE AND FORECAST, BY MAGNETIC RESONANCE IMAGING
  • FIGURE 17.MARKET SIZE AND FORECAST, BY POSITRON EMISSION TOMOGRAPHY
  • FIGURE 18.MARKET SIZE AND FORECAST, BY COMPUTER TOMOGRAPHY
  • FIGURE 19.MARKET SIZE AND FORECAST, BY MAMMOGRAPHY
  • FIGURE 20.MARKET SIZE AND FORECAST, BY ULTRASOUND
  • FIGURE 21.COMPARATIVE ANALYSIS OF CANCER BIOMARKERS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2019 & 2027 ($MILLION)
  • FIGURE 22.MARKET SIZE AND FORECAST, BY IMMUNOHISTOCHEMISTRY TESTS
  • FIGURE 23.MARKET SIZE AND FORECAST, BY ENZYME-LINKED IMMUNOSORBENT ASSAY
  • FIGURE 24.MARKET SIZE AND FORECAST, BY FLOW CYTOMETRY
  • FIGURE 25.COMPARATIVE ANALYSIS OF CANCER BIOMARKERS MARKET FOR CYTOGENETICS-BASED TESTS, BY COUNTRY, 2019 & 2027 ($MILLION)
  • FIGURE 26.MARKET SIZE AND FORECAST, BY IN-SITU HYBRIDIZATION
  • FIGURE 27.MARKET SIZE AND FORECAST, BY IN-SITU HYBRIDIZATION
  • FIGURE 28.COMPARATIVE ANALYSIS OF CANCER BIOMARKERS MARKET FOR GENETIC BIOMARKERS, BY COUNTRY, 2019 & 2027 ($MILLION)
  • FIGURE 29.COMPARATIVE ANALYSIS OF CANCER BIOMARKERS MARKET FOR PROTEIN BIOMARKERS, BY COUNTRY, 2019 & 2027 ($MILLION)
  • FIGURE 30.COMPARATIVE ANALYSIS OF CANCER BIOMARKERS MARKET FOR GLYCO-BIOMARKERS, BY COUNTRY, 2019 & 2027 ($MILLION)
  • FIGURE 31.COMPARATIVE ANALYSIS OF CANCER BIOMARKERS MARKET FOR BREAST CANCER, BY COUNTRY, 2019 & 2027 ($MILLION)
  • FIGURE 32.COMPARATIVE ANALYSIS OF CANCER BIOMARKERS MARKET FOR LUNG CANCER, BY COUNTRY, 2019 & 2027 ($MILLION)
  • FIGURE 33.COMPARATIVE ANALYSIS OF CANCER BIOMARKERS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2019 & 2027 ($MILLION)
  • FIGURE 34.COMPARATIVE ANALYSIS OF CANCER BIOMARKERS MARKET FOR PROSTATE CANCER, BY COUNTRY, 2019 & 2027 ($MILLION)
  • FIGURE 35.COMPARATIVE ANALYSIS OF CANCER BIOMARKERS MARKET FOR STOMACH CANCER, BY COUNTRY, 2019 & 2027 ($MILLION)
  • FIGURE 36.COMPARATIVE ANALYSIS OF CANCER BIOMARKERS MARKET FOR OTHERS CANCER, BY COUNTRY, 2019 & 2027 ($MILLION)
  • FIGURE 37.COMPARATIVE ANALYSIS OF CANCER BIOMARKERS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2019 & 2027 ($MILLION)
  • FIGURE 38.COMPARATIVE ANALYSIS OF CANCER BIOMARKERS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT CANCER, BY COUNTRY, 2019 & 2027 ($MILLION)
  • FIGURE 39.COMPARATIVE ANALYSIS OF CANCER BIOMARKERS MARKET FOR PROGNOSTICS, BY COUNTRY, 2019 & 2027 ($MILLION)
  • FIGURE 40.COMPARATIVE ANALYSIS OF CANCER BIOMARKERS MARKET FOR RISK ASSESSMENT, BY COUNTRY, 2019 & 2027 ($MILLION)
  • FIGURE 41.COMPARATIVE ANALYSIS OF CANCER BIOMARKERS MARKET FOR OTHERS, BY COUNTRY, 2019 & 2027 ($MILLION)
  • FIGURE 42.ABBOTT: NET SALES, 2016-2018 ($MILLION)
  • FIGURE 43.ABBOTT: REVENUE SHARE BY SEGMENT, 2018 (%)
  • FIGURE 44.ABBOTT: REVENUE SHARE BY REGION, 2018 (%)
  • FIGURE 45.BIO-RAD: NET SALES, 2016-2018 ($MILLION)
  • FIGURE 46.BIO-RAD: REVENUE SHARE BY SEGMENT, 2018 (%)
  • FIGURE 47.BIO-RAD: REVENUE SHARE BY REGION, 2018 (%)
  • FIGURE 48.BMS: NET SALES, 2016-2018 ($MILLION)
  • FIGURE 49.BMS: REVENUE SHARE BY REGION, 2018 (%)
  • FIGURE 50.EXACT SCIENCES: NET SALES, 2016-2018 ($MILLION)
  • FIGURE 51.ROCHE: NET SALES, 2016-2018 ($MILLION)
  • FIGURE 52.ROCHE: REVENUE SHARE BY SEGMENT, 2018 (%)
  • FIGURE 53.ROCHE: REVENUE SHARE BY SEGMENT, 2018 (%)
  • FIGURE 54.MERCK GROUP: NET SALES, 2016-2018 ($MILLION)
  • FIGURE 55.MERCK GROUP: REVENUE SHARE BY SEGMENT, 2018 (%)
  • FIGURE 56.MERCK GROUP: REVENUE SHARE BY REGION, 2018 (%)
  • FIGURE 57.PERKINELMER: NET SALES, 2016-2018 ($MILLION)
  • FIGURE 58.PERKINELMER: REVENUE SHARE BY SEGMENT, 2018 (%)
  • FIGURE 59.PERKINELMER: REVENUE SHARE BY REGION, 2018 (%)
  • FIGURE 60.QIAGEN: NET SALES, 2016-2018 ($MILLION)
  • FIGURE 61.QIAGEN: REVENUE SHARE BY SEGMENT, 2018 (%)
  • FIGURE 62.QIAGEN: REVENUE SHARE BY REGION, 2018 (%)
  • FIGURE 63.SIEMENS: NET SALES, 2016-2018 ($MILLION)
  • FIGURE 64.SIEMENS: REVENUE SHARE BY SEGMENT, 2018 (%)
  • FIGURE 65.SIEMENS: REVENUE SHARE BY REGION, 2018(%)
  • FIGURE 66.TERUMO: NET SALES, 2016-2018 ($MILLION)
  • FIGURE 67.THERMO FISCHER: REVENUE SHARE BY SEGMENT, 2018 (%)
  • FIGURE 68.THERMO FISCHER: REVENUE SHARE BY REGION, 2018 (%)
目次
Product Code: A01124

Title:
Cancer Biomarkers Market by Profiling Technology (Omic Technologies, Imaging Technologies, Immunoassays, and Cytogenetics Based Tests), Biomolecule (Genetic Biomarkers, Protein Biomarkers, and Glyco-biomarkers), Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Stomach Cancer, and Others), and Application (Diagnostics, Drug Discovery and Development, Prognostics,Risk Assessment, and Others): Global Opportunity Analysis and Industry Forecast, 2020-2027.

The global cancer biomarkers market was valued at $10,944.08 million in 2019, and is projected to reach $26,979.50 million by 2027, registering a CAGR of 11.8% from 2020 to 2027.

Cancer biomarkers are traceable substances or molecules that indicate the existence of cancerous cells in the body. The prevention of cancer by diagnosing and analyzing various cancer biomarkers using different diagnostic techniques is a profound approach to obtain rapid results for treatment. There are various types of biomarkers such as proteins, peptides, antibodies, and nucleic acids. Presence of these biomarkers in tissues, urine, serum, blood, and other body fluids indicate an abnormal process or a disease. Various such biomarkers for cancer indications have been studied and are being used for diagnostics, prognostics, personalized medicines, and surrogate endpoints. The identification of different types of biomarkers is an integral part of various industries such as healthcare and pharmaceuticals.

The global cancer biomarkers market is expected to witness a significant growth during the forecast period due to increase in prevalence of various types of cancers such as breast, prostate, and lung cancer. In addition, surge in importance of biological & targeted drug therapies, technological advancements, accuracy, and reliability of cancer biomarkers also contribute toward the growth of the market. Moreover, increase in investments from governments and public & private sector toward R&D for cancer diagnostics have a positive impact on the market. However, high cost of drug development, threat of failure associated with cancer treatment, and unregulated government regulations and reimbursement policies hamper the market growth. In contrast, advancements of cancer research and significant unmet need for cancer diagnosis are anticipated to provide new opportunities for the cancer biomarkers market.

The market is segmented on the basis of profiling technology, biomolecule, cancer type, application, and region. By profiling technology, the market is bifurcated into omic technologies, imaging technologies, immunoassays, and cytogenetics-based tests. On the basis of biomolecules, the market is segmented into genetic biomarkers, protein biomarkers, and glyco-biomarkers. By biomolecule, the market is segmented into genetic biomarkers, protein biomarkers, and glyco-biomarkers. By cancer type, the market is segmented as breast cancer, lung cancer, prostate cancer, colorectal cancer, stomach cancer, and others. Based on application, the market is segmented across diagnostics, drug discovery and development, prognostics, risk assessment, and others. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS

The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.

It offers a quantitative analysis from 2019 to 2027, which is expected to enable the stakeholders to capitalize on prevailing market opportunities.

Comprehensive analysis of all geographical regions is provided to determine the prevailing opportunities.

Key players are profiled, and their strategies are analyzed thoroughly to understand the competitive outlook of the global market.

KEY MARKET SEGMENTS

By Profiling Technology

  • Omic Technologies
  • Imaging Technologies
  • Immunoassays
  • Cytogenetics-based Tests

By Biomolecule

  • Genetic Biomarkers
  • Protein Biomarkers
  • Glyco-biomarkers

By Cancer Type

  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Stomach Cancer
  • Others

By Application

  • Diagnostics
  • Drug Discovery and Development
  • Prognostics
  • Risk Assessment
  • Others

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • United Arab Emirates
  • Rest of LAMEA
  • LIST OF KEY PLAYERS PROFILED IN THE REPORT
  • Abbott Laboratories
  • Bio-Rad Laboratories, Inc.
  • Bristol-Myers Squibb Compnay
  • Exact Sciences Corporation
  • F.Hoffmann-La Roche Ltd.
  • Merck KGaA
  • PerkinElmer, Inc.
  • Qiagen N.V.
  • Siemens AG
  • Thermo Fisher Scientific, Inc.

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key benefits for stakeholders
  • 1.3.Key market segments
    • 1.3.1.List of key players profiled in the report
  • 1.4.Research methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Biomarker Diagnosis vs. Conventional Diagnosis
  • 3.3.Key findings
    • 3.3.1.Top investment pockets
  • 3.4.Porter's five forces analysis
    • 3.4.1.Bargaining power of buyers
    • 3.4.2.Bargaining power of suppliers
    • 3.4.3.Thereat of new entrants
    • 3.4.4.Threat of substitutes
    • 3.4.5.Intensity of competitive rivalry
  • 3.5.Top player positioning, 2019
  • 3.6.Market dynamics
    • 3.6.1.Drivers
      • 3.6.1.1.Rise in incidence and prevalence of various cancer types
      • 3.6.1.2.Growth in importance of biological and targeted drug therapies
      • 3.6.1.3.Increase in acquisitions and collaborations
      • 3.6.1.4.Increase in technological advancements
      • 3.6.1.5.High accuracy and reliability
      • 3.6.1.6.Rise in investment from government, public, and private sectors
      • 3.6.1.7.Increase in clinical trials
      • 3.6.1.8.Growth in popularity of personalized medicine and companion diagnostics
    • 3.6.2.Restraint
      • 3.6.2.1.High cost of drug development and threat of failure
      • 3.6.2.2.Unregulated government regulation and reimbursement policies
      • 3.6.2.3.Adverse effects of cancer drug therapy
    • 3.6.3.Opportunity
      • 3.6.3.1.Advancement of cancer drugs research
      • 3.6.3.2.Increased focus towards advanced treatment protocols
      • 3.6.3.3.Significant unmet need in cancer diagnosis
      • 3.6.3.4.Increased awareness to reduce healthcare costs
      • 3.6.3.5.Opportunities in emerging economies
    • 3.6.4.Impact Analyses
  • 3.7.PATENT ANALYSIS
  • 3.8.Clinical Trials Analysis

CHAPTER 4:CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY

  • 4.1.Overview
    • 4.1.1.Market size and forecast, by profiling technologies
  • 4.2.OMIC TECHNOLOGIES
    • 4.2.1.Key market trends and growth opportunities
    • 4.2.2.Market size and forecast, by region
    • 4.2.3.Market analysis, by country
    • 4.2.4.Market size and forecast, by type
    • 4.2.5.Genomics
      • 4.2.5.1.Market Size and forecast
      • 4.2.5.2.Next Generation Sequencing (NGS)
      • 4.2.5.3.Microarray
      • 4.2.5.4.Polymerase chain reaction (PCR)
    • 4.2.6.Proteomics
      • 4.2.6.1.Market size and forecast
      • 4.2.6.2.Mass spectrometry
      • 4.2.6.3.2D gel electrophoresis
      • 4.2.6.4.Protein microarray technology
      • 4.2.6.5.Antibody array technology
      • 4.2.6.6.Peptide array technology
    • 4.2.7.Other omic technologies
      • 4.2.7.1.Market size and forecast
      • 4.2.7.2.Metabolomics
      • 4.2.7.3.Glycomics
  • 4.3.IMAGING TECHNOLOGIES
    • 4.3.1.Key market trends and growth opportunities
    • 4.3.2.Market size and forecast, by region
    • 4.3.3.Market analysis, by countries
    • 4.3.4.Market size and forecast, by type
    • 4.3.5.Magnetic resonance imaging (MRI)
      • 4.3.5.1.Market size and forecast
    • 4.3.6.Positron emission tomography (PET)
      • 4.3.6.1.Market size and forecast
    • 4.3.7.Computed tomography (CT)
      • 4.3.7.1.Market size and forecast
    • 4.3.8.Mammography
      • 4.3.8.1.Market size and forecast
    • 4.3.9.Ultrasound
      • 4.3.9.1.Market size and forecast
  • 4.4.IMMUNOASSAYS
    • 4.4.1.Key market trends and growth opportunities
    • 4.4.2.Market size and forecast, by region
    • 4.4.3.Market analysis, by country
    • 4.4.4.Market size and forecast, by type
    • 4.4.5.Immunohistochemistry (IHC) tests
      • 4.4.5.1.Market size and forecast
    • 4.4.6.Enzyme-linked immunosorbent assay (ELISA)
      • 4.4.6.1.Market size and forecast
    • 4.4.7.Flow cytometry
      • 4.4.7.1.Market size and forecast
  • 4.5.CYTOGENETICS-BASED TESTS
    • 4.5.1.Key market trends and growth opportunities
    • 4.5.2.Market size and forecast, by region
    • 4.5.3.Market analysis, by country
    • 4.5.4.Market size and forecast, by type
    • 4.5.5.In-situ hybridization
      • 4.5.5.1.Market size and forecast
    • 4.5.6.Others
      • 4.5.6.1.Market size and forecast

CHAPTER 5:CANCER BIOMARKERS MARKET, BY BIOMOLECULE

  • 5.1.Overview
    • 5.1.1.Market size and forecast
  • 5.2.Genetic Biomarkers
    • 5.2.1.Market size and forecast, by region
    • 5.2.2.Market analysis, by country
  • 5.3.Protein Biomarkers
    • 5.3.1.Market size and forecast, by region
    • 5.3.2.Market analysis, by country
  • 5.4.Glyco-Biomarkers
    • 5.4.1.Market size and forecast, by region
    • 5.4.2.Market analysis, by country135CHAPTER 6:CANCER BIOSENSORS MARKET, BY CANCER TYPE
  • 6.1.Overview
    • 6.1.1.Market size and forecast
  • 6.2.Breast Cancer
    • 6.2.1.Market size and forecast, by region
    • 6.2.2.Market analysis, by country
  • 6.3.Lung Cancer
    • 6.3.1.Market size and forecast, by region
    • 6.3.2.Market analysis, by country
  • 6.4.Colorectal cancer
    • 6.4.1.Market size and forecast, by region
    • 6.4.2.Market analysis, by country
  • 6.5.Prostate cancer
    • 6.5.1.Market size and forecast, by region
    • 6.5.2.Market analysis, by country
  • 6.6.Stomach cancer
    • 6.6.1.Market size and forecast, by region
    • 6.6.2.Market analysis, by country
  • 6.7.Others
    • 6.7.1.Market size and forecast, by region
    • 6.7.2.Market analysis, by country

CHAPTER 7:CANCER BIOMARKER MARKET, BY APPLICATION

  • 7.1.Overview
    • 7.1.1.Market size and forecast
  • 7.2.Diagnostics
    • 7.2.1.Market size and forecast, by region
    • 7.2.2.Market analysis, by country
  • 7.3.Drug Discovery and Development
    • 7.3.1.Market size and forecast, by region
    • 7.3.2.Market analysis, by country
  • 7.4.Prognostics
    • 7.4.1.Market size and forecast, by region
    • 7.4.2.Market analysis, by country
  • 7.5.Risk Assessment
    • 7.5.1.Market size and forecast, by region
    • 7.5.2.Market analysis, by country
  • 7.6.Others
    • 7.6.1.Market size and forecast, by region
    • 7.6.2.Market analysis, by country

CHAPTER 8:CANCER BIOMARKERS MARKET, BY REGION

  • 8.1.Overview
    • 8.1.1.Market size and forecast
  • 8.2.North America
    • 8.2.1.Key market trends and opportunities
    • 8.2.2.Market analysis by country
      • 8.2.2.1.U.S.
      • 8.2.2.1.1.U.S. market size and forecast, by profiling technologies
      • 8.2.2.1.2.U.S. market size and forecast, by biomolecules
      • 8.2.2.1.3.U.S. market size and forecast, by cancer type
      • 8.2.2.1.4.U.S. market size and forecast, by application
      • 8.2.2.2.Canada
      • 8.2.2.2.1.Canada market size and forecast, by profiling technologies
      • 8.2.2.2.2.Canada market size and forecast, by biomolecules
      • 8.2.2.2.3.Canada market size and forecast, by cancer type
      • 8.2.2.2.4.Canada market size and forecast, by application
      • 8.2.2.3.Mexico
      • 8.2.2.3.1.Mexico market size and forecast, by profiling technologies
      • 8.2.2.3.2.Mexico market size and forecast, by biomolecules
      • 8.2.2.3.3.Mexico market size and forecast, by cancer type
      • 8.2.2.3.4.Mexico market size and forecast, by application
    • 8.2.3.North America market size and forecast, by profiling technologies
    • 8.2.4.North America market size and forecast, by biomolecules
    • 8.2.5.North America market size and forecast, by cancer type
    • 8.2.6.North America market size and forecast, by application
  • 8.3.Europe
    • 8.3.1.Key market trends and opportunities
    • 8.3.2.Market analysis by country
      • 8.3.2.1.Germany
      • 8.3.2.1.1.Germany market size and forecast, by profiling technologies
      • 8.3.2.1.2.Germany market size and forecast, by biomolecules
      • 8.3.2.1.3.Germany market size and forecast, by cancer type
      • 8.3.2.1.4.Germany market size and forecast, by application
      • 8.3.2.2.France
      • 8.3.2.2.1.France market size and forecast, by profiling technologies
      • 8.3.2.2.2.France market size and forecast, by biomolecules
      • 8.3.2.2.3.France market size and forecast, by cancer type
      • 8.3.2.2.4.France market size and forecast, by application
      • 8.3.2.3.UK
      • 8.3.2.3.1.UK market size and forecast, by profiling technologies
      • 8.3.2.3.2.UK market size and forecast, by biomolecules
      • 8.3.2.3.3.UK market size and forecast, by cancer type
      • 8.3.2.3.4.UK market size and forecast, by application
      • 8.3.2.4.Italy
      • 8.3.2.4.1.Italy market size and forecast, by profiling technologies
      • 8.3.2.4.2.Italy market size and forecast, by biomolecules
      • 8.3.2.4.3.Italy market size and forecast, by cancer type
      • 8.3.2.4.4.Italy market size and forecast, by application
      • 8.3.2.5.Russia
      • 8.3.2.5.1.Russia market size and forecast, by profiling technologies
      • 8.3.2.5.2.Russia market size and forecast, by biomolecules
      • 8.3.2.5.3.Russia market size and forecast, by cancer type
      • 8.3.2.5.4.Russia market size and forecast, by application
      • 8.3.2.6.Rest of Europe
      • 8.3.2.6.1.Rest of Europe market size and forecast, by profiling technologies
      • 8.3.2.6.2.Rest of Europe market size and forecast, by biomolecules
      • 8.3.2.6.3.Rest of Europe market size and forecast, by cancer type
      • 8.3.2.6.4.Rest of Europe market size and forecast, by application
    • 8.3.3.Europe market size and forecast, by profiling technologies
    • 8.3.4.Europe market size and forecast, by biomolecules
    • 8.3.5.Europe market size and forecast, by cancer type
    • 8.3.6.Europe market size and forecast, by application
  • 8.4.Asia-Pacific
    • 8.4.1.Key market trends and opportunities
    • 8.4.2.Market analysis by country
      • 8.4.2.1.Japan
      • 8.4.2.1.1.Japan market size and forecast, by profiling technologies
      • 8.4.2.1.2.Japan market size and forecast, by biomolecules
      • 8.4.2.1.3.Japan market size and forecast, by cancer type
      • 8.4.2.1.4.Japan market size and forecast, by application
      • 8.4.2.2.China
      • 8.4.2.2.1.China market size and forecast, by profiling technologies
      • 8.4.2.2.2.China market size and forecast, by biomolecules
      • 8.4.2.2.3.China market size and forecast, by cancer type
      • 8.4.2.2.4.China market size and forecast, by application
      • 8.4.2.3.Australia
      • 8.4.2.3.1.Australia market size and forecast, by profiling technologies
      • 8.4.2.3.2.Australia market size and forecast, by biomolecules
      • 8.4.2.3.3.Australia market size and forecast, by cancer type
      • 8.4.2.3.4.Australia market size and forecast, by application
      • 8.4.2.4.India
      • 8.4.2.4.1.India market size and forecast, by profiling technologies
      • 8.4.2.4.2.India market size and forecast, by biomolecules
      • 8.4.2.4.3.India market size and forecast, by cancer type
      • 8.4.2.4.4.India market size and forecast, by application
      • 8.4.2.5.Rest of Asia-Pacific
      • 8.4.2.5.1.Rest of Asia-Pacific market size and forecast, by profiling technologies
      • 8.4.2.5.2.Rest of Asia-Pacific market size and forecast, by biomolecules
      • 8.4.2.5.3.Rest of Asia-Pacific market size and forecast, by cancer type
      • 8.4.2.5.4.Rest of Asia-Pacific market size and forecast, by application
    • 8.4.3.Asia-Pacific market size and forecast, by profiling technologies
    • 8.4.4.Asia-Pacific market size and forecast, by biomolecules
    • 8.4.5.Asia-Pacific market size and forecast, by cancer type
    • 8.4.6.Asia-Pacific market size and forecast, by application
  • 8.5.LAMEA
    • 8.5.1.Key market trends and opportunities
    • 8.5.2.Market analysis by country
      • 8.5.2.1.Brazil
      • 8.5.2.1.1.Brazil market size and forecast, by profiling technologies
      • 8.5.2.1.2.Brazil market size and forecast, by biomolecules
      • 8.5.2.1.3.Brazil market size and forecast, by cancer type
      • 8.5.2.1.4.Brazil market size and forecast, by application
      • 8.5.2.2.Saudi Arabia
      • 8.5.2.2.1.Saudi Arabia market size and forecast, by profiling technologies
      • 8.5.2.2.2.Saudi Arabia market size and forecast, by biomolecules
      • 8.5.2.2.3.Saudi Arabia market size and forecast, by cancer type
      • 8.5.2.2.4.Saudi Arabia market size and forecast, by application
      • 8.5.2.3.United Arab Emirates
      • 8.5.2.3.1.United Arab Emirates market size and forecast, by profiling technologies
      • 8.5.2.3.2.United Arab Emirates market size and forecast, by biomolecules
      • 8.5.2.3.3.United Arab Emirates market size and forecast, by cancer type
      • 8.5.2.3.4.United Arab Emirates market size and forecast, by application
      • 8.5.2.4.Rest of LAMEA
      • 8.5.2.4.1.Rest of LAMEA market size and forecast, by profiling technologies
      • 8.5.2.4.2.Rest of LAMEA market size and forecast, by biomolecules
      • 8.5.2.4.3.Rest of LAMEA market size and forecast, by cancer type
      • 8.5.2.4.4.Rest of LAMEA market size and forecast, by application
    • 8.5.3.LAMEA market size and forecast, by profiling technologies
    • 8.5.4.LAMEA market size and forecast, by biomolecules
    • 8.5.5.LAMEA market size and forecast, by cancer type
    • 8.5.6.LAMEA market size and forecast, by application

CHAPTER 9:COMPANY PROFILES

  • 9.1.Abbott Laboratories
    • 9.1.1.Company overview
    • 9.1.2.Company snapshot
    • 9.1.3.Operating business segments
    • 9.1.4.Product portfolio
    • 9.1.5.Business performance
  • 9.2.BIO-RAD LABORATORIES, INC.
    • 9.2.1.Company overview
    • 9.2.2.Company snapshot
    • 9.2.3.Operating business segments
    • 9.2.4.Product Portfolio
    • 9.2.5.Business performance
  • 9.3.Bristol-Myers Squibb Company
    • 9.3.1.Company overview
    • 9.3.2.Company snapshot
    • 9.3.3.Operating business segments
    • 9.3.4.Product portfolio
    • 9.3.5.Business performance
    • 9.3.6.Key strategic moves and developments
  • 9.5.EXACT SCIENCES CORPORATION
    • 9.5.1.Company overview
    • 9.5.2.Company snapshot
    • 9.5.3.Operating business segments
    • 9.5.4.Product portfolio
    • 9.5.5.Business performance
    • 9.5.6.Key strategic moves and developments
  • 9.6.F. HOFFMANN-LA ROCHE LTD.
    • 9.6.1.Company overview
    • 9.6.2.Company snapshot
    • 9.6.3.Operating business segments
    • 9.6.4.Product portfolio
    • 9.6.5.Business performance

305

    • 9.6.6.Key strategic moves and developments
  • 9.7.Merck KGaA
    • 9.7.1.Company overview
    • 9.7.2.Company snapshot
    • 9.7.3.Operating business segments
    • 9.7.4.Product portfolio
    • 9.7.5.Business performance
    • 9.7.6.Key strategic moves and developments
  • 9.8.PERKINELMER, INC.
    • 9.8.1.Company overview
    • 9.8.2.Company snapshot
    • 9.8.3.Operating business segments
    • 9.8.4.Product portfolio
    • 9.8.5.Business performance
    • 9.8.6.Key strategic moves and developments
  • 9.9.QIAGEN N.V.
    • 9.9.1.Company overview
    • 9.9.2.Company snapshot
    • 9.9.3.Operating business segments
    • 9.9.4.Product portfolio
    • 9.9.5.Business performance
    • 9.9.6.Key strategic moves and developments
  • 9.10.Siemens AG
    • 9.10.1.Company overview
    • 9.10.2.Company snapshot
    • 9.10.3.Operating business segments
    • 9.10.4.Product portfolio
    • 9.10.5.Business performance
  • 9.11.THERMO FISHER SCIENTIFIC, INC.
    • 9.11.1.Company overview
    • 9.11.2.Company snapshot
    • 9.11.3.Operating business segments
    • 9.11.4.Product portfolio
    • 9.11.5.Business performance
    • 9.11.6.Key strategic moves and developments